WO2016137235A3 - 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물 - Google Patents

마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물 Download PDF

Info

Publication number
WO2016137235A3
WO2016137235A3 PCT/KR2016/001828 KR2016001828W WO2016137235A3 WO 2016137235 A3 WO2016137235 A3 WO 2016137235A3 KR 2016001828 W KR2016001828 W KR 2016001828W WO 2016137235 A3 WO2016137235 A3 WO 2016137235A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
treating cancer
active ingredient
microrna
mir
Prior art date
Application number
PCT/KR2016/001828
Other languages
English (en)
French (fr)
Other versions
WO2016137235A9 (ko
WO2016137235A2 (ko
Inventor
이태우
심상현
유웅식
박한오
Original Assignee
(주)바이오니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2017545217A priority Critical patent/JP6538183B2/ja
Priority to US15/553,097 priority patent/US10351849B2/en
Priority to CA2977624A priority patent/CA2977624C/en
Priority to AU2016224201A priority patent/AU2016224201B2/en
Priority to EP16755885.7A priority patent/EP3263135B1/en
Priority to BR112017018318-8A priority patent/BR112017018318A2/ko
Application filed by (주)바이오니아 filed Critical (주)바이오니아
Priority to RU2017132895A priority patent/RU2686313C2/ru
Priority to CN201680018165.9A priority patent/CN107454843B/zh
Publication of WO2016137235A2 publication Critical patent/WO2016137235A2/ko
Publication of WO2016137235A3 publication Critical patent/WO2016137235A3/ko
Publication of WO2016137235A9 publication Critical patent/WO2016137235A9/ko
Priority to US16/371,026 priority patent/US10612026B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 miR-3670, miR-4477a, miR-8078 로 구성된 군에서 선택되는 하나 이상의 miRNA를 유효 성분으로 포함하는 암 치료용 약학 조성물에 관한 것이다. 본 발명에 따른 암 치료용 약학 조성물은 암 세포의 증식 억제 및 사멸을 유발하는 효과가 우수하다. 따라서 본 발명의 약학 조성물은 항암 치료제로서 유용하게 사용될 수 있다.
PCT/KR2016/001828 2015-02-25 2016-02-25 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물 WO2016137235A2 (ko)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US15/553,097 US10351849B2 (en) 2015-02-25 2016-02-25 Pharmaceutical composition for treating cancer comprising microrna as active ingredient
CA2977624A CA2977624C (en) 2015-02-25 2016-02-25 Pharmaceutical composition for treating cancer comprising microrna as active ingredient
AU2016224201A AU2016224201B2 (en) 2015-02-25 2016-02-25 Pharmaceutical composition for treating cancer comprising microRNA as active ingredient
EP16755885.7A EP3263135B1 (en) 2015-02-25 2016-02-25 Pharmaceutical composition for treating cancer comprising microrna as active ingredient
BR112017018318-8A BR112017018318A2 (ko) 2015-02-25 2016-02-25 A pharmaceutical composition for treating cancer comprising a micro RNA as an active ingredient
JP2017545217A JP6538183B2 (ja) 2015-02-25 2016-02-25 マイクロｒｎａを有効成分として含む癌治療用医薬組成物
RU2017132895A RU2686313C2 (ru) 2015-02-25 2016-02-25 Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента
CN201680018165.9A CN107454843B (zh) 2015-02-25 2016-02-25 包含微小核糖核酸作为活性成分的用于治疗癌症的药物组合物
US16/371,026 US10612026B2 (en) 2015-02-25 2019-03-31 Pharmaceutical composition for treating cancer comprising microrna as active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150026557 2015-02-25
KR10-2015-0026557 2015-02-25

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/553,097 A-371-Of-International US10351849B2 (en) 2015-02-25 2016-02-25 Pharmaceutical composition for treating cancer comprising microrna as active ingredient
US16/371,026 Division US10612026B2 (en) 2015-02-25 2019-03-31 Pharmaceutical composition for treating cancer comprising microrna as active ingredient

Publications (3)

Publication Number Publication Date
WO2016137235A2 WO2016137235A2 (ko) 2016-09-01
WO2016137235A3 true WO2016137235A3 (ko) 2016-10-20
WO2016137235A9 WO2016137235A9 (ko) 2016-11-24

Family

ID=56789628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/001828 WO2016137235A2 (ko) 2015-02-25 2016-02-25 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물

Country Status (10)

Country Link
US (2) US10351849B2 (ko)
EP (1) EP3263135B1 (ko)
JP (1) JP6538183B2 (ko)
KR (2) KR101862080B1 (ko)
CN (2) CN113633656A (ko)
AU (1) AU2016224201B2 (ko)
BR (1) BR112017018318A2 (ko)
CA (2) CA3134991A1 (ko)
RU (1) RU2686313C2 (ko)
WO (1) WO2016137235A2 (ko)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102510768B1 (ko) 2014-06-12 2023-03-16 국립연구개발법인 고쿠리츠간켄큐센터 전립선암 검출 키트 또는 디바이스 및 검출 방법
KR101861738B1 (ko) * 2016-08-24 2018-05-29 (주)바이오니아 마이크로 rna를 포함하는 이중나선 올리고 rna 구조체
CN107058474B (zh) * 2016-11-03 2020-09-01 中国人民解放军陆军军医大学 一种通过血浆microRNA-3591-3p诊断急性高山病的诊断试剂盒
KR20180075139A (ko) * 2016-12-26 2018-07-04 한국원자력의학원 Ccnd3 또는 pak2 유전자의 발현을 저해하는 암을 치료하기 위한 약학적 조성물
WO2018231034A2 (ko) * 2017-06-16 2018-12-20 (주)프로스테믹스 암의 예방 또는 치료용 약학적 조성물
CA3083756A1 (en) * 2017-11-09 2019-05-16 Hiroshima University Pharmaceutical composition for cancer therapy comprising mirna
KR102145176B1 (ko) * 2017-11-27 2020-08-18 (주)프로스테믹스 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
KR102138495B1 (ko) * 2017-11-27 2020-07-28 (주)프로스테믹스 이중 가닥의 올리고뉴클레오티드 및 그 제조 방법
KR102189987B1 (ko) * 2017-11-27 2020-12-11 (주)프로스테믹스 miRNA를 포함하는 탈모 방지 또는 발모 촉진용 조성물
KR102189991B1 (ko) * 2017-11-27 2020-12-11 (주)프로스테믹스 miRNA를 포함하는 상처 치료 또는 피부 개선용 조성물
CN107881237B (zh) * 2017-12-01 2020-11-20 唐山市人民医院 肺癌诊断标记物microRNA-4317及在药物和诊断试剂盒中的应用
KR102141124B1 (ko) 2018-01-30 2020-08-04 (주)바이오니아 이중 가닥 miRNA를 포함하는 이중나선 올리고뉴클레오타이드 구조체 및 이의 용도
US10987428B2 (en) * 2018-06-01 2021-04-27 City Of Hope Phosphorothioate-conjugated miRNAs and methods of using the same
JP7378739B2 (ja) * 2018-08-10 2023-11-14 東レ株式会社 前立腺がんの検出のためのキット、デバイス及び方法
KR102178919B1 (ko) * 2018-11-26 2020-11-13 순천향대학교 산학협력단 당뇨병성 신증 진단을 위한 마이크로rna 바이오마커 및 이의 용도
KR102133205B1 (ko) 2018-12-05 2020-07-13 충북대학교 산학협력단 PNA-pHLIP 접합체를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
KR102418779B1 (ko) * 2018-12-12 2022-07-08 (주)프로스테믹스 신규한 miRNA 유사체 및 이의 용도
WO2020235671A1 (ja) * 2019-05-23 2020-11-26 国立大学法人大阪大学 性ホルモン非感受性ｇｒｅｂ１陽性腫瘍の治療剤
CN110184338B (zh) * 2019-05-31 2023-04-07 南方医科大学第三附属医院（广东省骨科研究院） 脑脊液外泌体miRNA在MMD诊断和治疗中的应用
WO2020246380A1 (ja) * 2019-06-05 2020-12-10 株式会社キャンサーステムテック 癌治療剤
KR102085260B1 (ko) 2019-06-19 2020-03-05 한국원자력의학원 Ccnd3 또는 pak2 유전자의 발현을 저해하는 암을 치료하기 위한 약학적 조성물
CN110607368B (zh) * 2019-09-19 2021-07-13 西安交通大学 miRNA3926-1基因作为胰腺癌诊断和疗效标志物的应用
CN111467504A (zh) * 2020-03-13 2020-07-31 南方医科大学 miR-4469在制备抗结直肠癌药物中的应用
CN111349704B (zh) * 2020-03-17 2020-11-24 河北医科大学第三医院 肝癌的诊断产品和治疗组合物
CN111387143A (zh) * 2020-04-02 2020-07-10 华北理工大学 miRNA-203a-3p在开发抑制胰腺癌药物中的应用
CN111466339A (zh) * 2020-04-02 2020-07-31 华北理工大学 miRNA-203a-3p在促进胰腺癌细胞增殖和迁移中的应用
WO2021240533A1 (en) * 2020-05-29 2021-12-02 National Institute Of Immunology Dna damage dependent microrna signature for cancers, methods and uses related thereto
CN114058697B (zh) * 2020-07-29 2023-08-18 四川大学华西医院 检测外泌体miR-6774-3p或miR-6776-5p的试剂的用途
CN114058698B (zh) * 2020-07-29 2023-08-15 四川大学华西医院 检测外泌体miR-6879-5p的试剂在制备甲状腺癌转移检测试剂盒中的用途
WO2022087600A1 (en) * 2020-10-20 2022-04-28 Duquesne University Of The Holy Spirit Micro rna interactions as therapeutic targets for covid-19 and other viral infections
CN112094913B (zh) * 2020-11-10 2021-03-30 广州市锐博生物科技有限公司 结直肠癌生物标志物及其用途
CN116847888A (zh) * 2021-02-25 2023-10-03 柏业公司 用于减轻毛发变白、促进毛发生长和/或预防或减轻脱发的包含双链miRNA作为活性成分的组合物
CN113041255B (zh) * 2021-04-13 2022-10-11 上海中医药大学 一种新发现miRNA–mRNA调控轴介导肺腺癌NCI-H1299细胞焦亡的方法
CN113981074A (zh) * 2021-12-10 2022-01-28 石河子大学 一种与2型糖尿病相关的microRNA及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140080894A1 (en) * 2011-03-02 2014-03-20 David L. McElligott Enhanced biodistribution of oligomers
WO2014100252A1 (en) * 2012-12-18 2014-06-26 University Of Washington Through Its Center For Commercialization Methods and compositions to modulate rna processing

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US15071A (en) * 1856-06-10 John h
BRPI0612334A2 (pt) * 2005-04-12 2009-01-27 Univ Libre Bruxelles uso de uma abordagem baseada em galectina-1 direcionada para rnai no tratamento do cÂncer
EP2167138A2 (en) 2007-06-08 2010-03-31 Asuragen, INC. Mir-34 regulated genes and pathways as targets for therapeutic intervention
KR101325186B1 (ko) * 2008-01-23 2013-11-07 (주)바이오니아 이중가닥 ｍｉＲＮＡ를 유효성분으로 포함하는 항암제
KR101707669B1 (ko) * 2008-04-17 2017-02-16 더 존스 홉킨스 유니버시티 약제-내성 종양에서 화학요법제 활성을 증강시키는 ｏｎ01910.ｎａ
WO2011069100A2 (en) * 2009-12-04 2011-06-09 Duke University Microrna and use thereof in identification of b cell malignancies
CN103505743A (zh) * 2012-06-21 2014-01-15 北京命码生科科技有限公司 含功能性microRNA/siRNA的细胞微粒子及其应用
JP6352269B2 (ja) 2012-09-26 2018-07-04 ミルクス セラピューティクス アクティーゼルスカブＭｉｒｒｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａ／Ｓ オフターゲットプロファイルの改善されたオリゴマー
US9730954B2 (en) 2012-11-16 2017-08-15 The Board Of Regents Of The University Of Texas System miRNAs as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers
CN112094913B (zh) * 2020-11-10 2021-03-30 广州市锐博生物科技有限公司 结直肠癌生物标志物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140080894A1 (en) * 2011-03-02 2014-03-20 David L. McElligott Enhanced biodistribution of oligomers
WO2014100252A1 (en) * 2012-12-18 2014-06-26 University Of Washington Through Its Center For Commercialization Methods and compositions to modulate rna processing

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CALIN, G. A. ET AL.: "MicroRNA Signatures in Human Cancers", NATURE REVIEWS CANCER, vol. 6, 2006, pages 857 - 866, XP002473506 *
KOTA, J. ET AL.: "Therapeutic MicroRNA Delivery suppresses Tumorigenesis in a Murine Liver Cancer Model", CELL, vol. 137, 2009, pages 1005 - 1017, XP055004118 *
LI, M. ET AL.: "MicroRNA-561 promotes Acetaminophen-induced Hepatotoxicity in HepG2 Cells and Primary Human Hepatocytes through Downregulation of the Nuclear Receptor Corepressor Dosage-sensitive Sex-reversal Adrenal Hypoplasia Coegenital Critical Region on the X Chromosome, Gene 1 (DAX-1", DRUG METABOLISM AND DISPOSITION, vol. 42, 2014, pages 44 - 61, XP055322501 *

Also Published As

Publication number Publication date
US20180030440A1 (en) 2018-02-01
CA2977624A1 (en) 2016-09-01
JP2018507866A (ja) 2018-03-22
US10612026B2 (en) 2020-04-07
RU2017132895A (ru) 2019-03-25
CA3134991A1 (en) 2016-09-01
US10351849B2 (en) 2019-07-16
JP6538183B2 (ja) 2019-07-03
EP3263135A2 (en) 2018-01-03
WO2016137235A9 (ko) 2016-11-24
KR101862080B1 (ko) 2018-07-04
AU2016224201A1 (en) 2017-09-21
KR20160103949A (ko) 2016-09-02
WO2016137235A2 (ko) 2016-09-01
CA2977624C (en) 2021-11-30
US20190218555A1 (en) 2019-07-18
RU2017132895A3 (ko) 2019-03-25
RU2686313C2 (ru) 2019-04-25
EP3263135B1 (en) 2020-01-15
KR101960067B1 (ko) 2019-03-20
CN113633656A (zh) 2021-11-12
KR20180054549A (ko) 2018-05-24
CN107454843A (zh) 2017-12-08
BR112017018318A2 (ko) 2018-07-10
AU2016224201B2 (en) 2018-07-05
EP3263135A4 (en) 2018-09-19
CN107454843B (zh) 2021-07-30

Similar Documents

Publication Publication Date Title
WO2016137235A3 (ko) 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물
EP3895717A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING WEISSELLA CIBARIA WIKIM28 AS ACTIVE SUBSTANCE
WO2016172134A3 (en) Novel compounds
NZ730803A (en) Methods for the preparation of ribosides
WO2016064082A3 (ko) 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
EP3279210A4 (en) Peptide having anticancer activity, and pharmaceutical composition and dietary supplement composition for preventing and treating cancer, both of which contain same as active ingredient
PH12016501527B1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
EP3539951A4 (en) NOVEL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER AND INFLAMMATORY DISEASES
EP3566702A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ALLERGIC DISEASES SUCH AS ASTHMA OR ATOPIA, CONSISTING OF BAICALEIN AS THE ACTIVE SUBSTANCE
EP3909597A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING AN OLIGOPEPTIDE AS ACTIVE INSTRUMENT
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
EP3964520A4 (en) NEW OLIGOPEPTIDE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER USING IT AS AN ACTIVE SUBSTANCE
IL268224A (en) A pharmaceutical compound for the prevention and treatment of pancreatic cancer, containing GOSSYPOL and PHENFORMIN as active ingredients
EP3311817A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF EYES DISEASES WITH IMATINIB AS AN ACTIVE SUBSTANCE
MY193423A (en) Oxadiazaspiro compounds for the treatment of drug abuse and addiction
EP3610866A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER, CONTAINING A MALATE-ASPARTATE SHUTTLE INHIBITOR AND ANTI-CANCER DRUG AS ACTIVE SUBSTANCES
EP3181137A4 (en) Pharmaceutical composition for preventing or treating gleevec-resistant leukemia, containing, as active ingredient, ginsenoside f1 or rg3
PH12017502426A1 (en) Solid pharmaceutical compositions for treating hcv
EP3398608A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER OR CANCER METASTASES WITH PSTL1-PRTEIN AS AN ACTIVE SUBSTANCE
EP3443975A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEARING LOSS COMPRISING OATOUS EXTRACT AS ACTIVE INGREDIENT
PH12018500132A1 (en) Solid pharmaceutical compositions for treating hcv
WO2015044961A3 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
EP3603647A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF GLAUCOMA, CONTAINING AN ADENOSINE DERIVATIVE
EP3417869A4 (en) COMPOSITION CONTAINING RHIZOMA PHRAGMITIS EXTRACT AS AN ACTIVE INGREDIENT FOR PREVENTING, IMPROVING OR TREATING DISEASES AFFECTED BY ANTI-CANCER AGENT'S SECONDARY EFFECT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16755885

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2977624

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017545217

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017018318

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2016755885

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016224201

Country of ref document: AU

Date of ref document: 20160225

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017132895

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112017018318

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170825